No Data
No Data
Hengrui Pharmaceutical (600276.SH): Subsidiary SHR-9539 Injection Obtains Drug Clinical Trial Approval Notice
Gelonghui, May 30丨Hengrui Pharmaceutical (600276.SH) announced that recently, the company's subsidiaries Shanghai Hengrui Pharmaceutical Co., Ltd. and Suzhou Shengdia Biomedical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-9539 injections and will conduct clinical trials in the near future. SHR-9539 injection is a class 1 therapeutic biological product. By inducing and activating T cells, it exerts a targeted effect on killing multiple myeloma cells. Currently, no similar drugs have been approved for marketing in China. Up to now, SHR-9539 injection-related projects have been accumulated
Hengrui Pharmaceuticals Gets Nod to Trial Vitiligo Drug
Jiangsu Hengrui Pharmaceuticals (SHA:600276) will conduct clinical trials on the SHR0302 alkaline gel as a treatment for vitiligo after obtaining the approval of Chinese drug regulator National Medica
Hengrui Pharmaceutical (600276.SH): SHR0302 alkali gel obtained drug clinical trial approval notice
Gelonghui May 29丨Hengrui Pharmaceutical (600276.SH) announced that it has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR0302 alkali gel, and will conduct clinical trials in the near future. SHR0302 alkali gel is a topical, highly selective JAK1 inhibitor. It can exert anti-inflammatory and immune-suppressing biological effects by improving local exposure and better inhibiting JAK1 signaling.
China Grants Clinical Trial Approval for Anti-Cancer Injections
China's medical products administrator approved Jiangsu Hengrui Pharmaceutical's clinical trials for the SHR-9839, SHR-A1921, and SHR-A2009 injectables, according to a Sunday filing by the Shanghai St
Hengrui Pharmaceutical (600276.SH): The subsidiary SHR-A1921 for injectable drugs will be included in the list of breakthrough treatment varieties announced
Gelonghui May 26 丨 Hengrui Pharmaceutical (600276.SH) announced that the injectable SHR-A1921 of the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. was proposed to be included in the publication list of breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration (referred to as the “Drug Review Center”). The publicity period is 7 days. SHR-A1921 for injection is an antibody-drug conjugate (ADC) targeting TROP-2 tumor-related antigen. By binding to the target antigen on the surface of tumor cells, the drug releases small molecules of toxins to kill tumor cells after being endocytosed into the cell. TROP-2 is a broad expression
Hengrui Pharma Gets China Drug Registration Certificate for Ovarian, Fallopian Tube Cancer Drugs
China's medical products administrator granted Jiangsu Hengrui Pharmaceuticals (SHA:600276) a drug registration certificate for its fluzoparib capsules for platinum-sensitive recurrent ovarian cancer
No Data